Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
STANDARD BIOTOOLS INC. director Eloi Fenel M reported equity awards consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, contingent on continued service. Each RSU converts into one common share at vesting, bringing direct common stock holdings to 335,299 shares after the award. He was also granted a stock option for 175,923 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026 and expiring on June 18, 2036.
STANDARD BIOTOOLS INC. director Kathy L. Hibbs reported equity awards that increase her stake in the company. On June 18, 2026, she received 99,116 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day prior to the next annual stockholders’ meeting, subject to continued service.
She also received a stock option for 175,923 shares of Common Stock at an exercise price of $0.8297 per share, becoming exercisable in twelve equal monthly installments beginning on July 18, 2026, also subject to continued service. After these awards, she directly owns 236,836 shares plus 175,923 stock options.
Standard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. Stockholders approved the company’s new 2026 Equity Incentive Plan and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan, increasing the shares of common stock reserved under the ESPP by 1,200,000 shares.
Three Class I directors were elected to serve until the 2029 annual meeting, and stockholders gave advisory approval to executive compensation for 2025. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026. On the April 24, 2026 record date, the company had 390,368,119 shares of common stock outstanding, and approximately 86.04% of voting power was represented at the meeting.
Viking Global Investors and affiliates filed a Schedule 13D reporting beneficial ownership of 58,651,170 shares of Standard BioTools common stock, or about 15% of the company. This stake is held through VGOP with 39,296,310 shares and VGOD with 19,354,860 shares, based on 390,368,119 shares outstanding as of May 4, 2026.
The filing follows conversion of all Series B-2 preferred stock into common stock. Viking has entered into a Voting Agreement to support Standard BioTools’ proposed merger with Treeline Biosciences, related share issuance, a corporate name change to Treeline Biosciences Holdings, Inc., a reverse stock split, and new post-closing equity plans. The agreement caps covered shares at 58,651,170 and restricts dispositions, and Viking notes a Rule 13d-1(e)(2) cooling-off period ending ten days after this filing.
Standard BioTools Inc. received an updated Schedule 13D/A from funds managed by Casdin Capital connected to a pending merger with Treeline Biosciences. Eli Casdin may be deemed to beneficially own 93,845,778 shares of common stock, or 23.9% of the class, including options and warrants.
Casdin-related funds collectively report sizable stakes, with Casdin Capital LLC itself reporting shared voting and dispositive power over 88,783,856 shares. The amendment discloses a June 6, 2026 merger agreement under which Treeline will become a wholly owned subsidiary and the issuer will be renamed Treeline Biosciences Holdings, Inc.
Casdin parties entered into a voting agreement to support stock issuance for the merger, the name change, a reverse stock split and new post-closing equity plans, subject to detailed conditions if the board changes its recommendation. They also signed a 180-day lock-up restricting sales of the combined company’s stock after closing.
Standard BioTools Inc. entered into an Agreement and Plan of Merger and Reorganization to combine with Treeline Biosciences, Inc. in an all‑stock merger. The Exchange Ratio ties to an assumed Treeline equity value of $2.5 billion and an assumed Standard BioTools equity value of $460 million, with former Standard BioTools stockholders expected to hold approximately 16% of the combined company on a fully diluted basis and former Treeline stockholders approximately 84%.
The Merger contemplates a Charter Amendment to change the company name to Treeline Biosciences Holdings, Inc., a possible Reverse Stock Split, assumption of Treeline equity awards and warrants, a CVR program with a maximum 76,000,000 shares available, customary closing conditions (including stockholder approvals, Form S-4 effectiveness and HSR clearance), a $16.1 million termination payment in specified circumstances and reimbursement of Treeline out-of-pocket fees up to $5 million. Standard BioTools expects closing in the second half of 2026.
Standard BioTools Inc. agreed to an all-stock merger with privately held Treeline Biosciences, creating a combined company focused on Treeline’s clinical-stage drug pipeline. Treeline will become a wholly owned subsidiary and the parent will be renamed Treeline Biosciences Holdings, Inc., with a potential reverse stock split at closing.
The deal values Treeline at $2.5 billion and Standard BioTools at about $460 million, based on net cash. On a fully diluted basis, former Standard BioTools stockholders are expected to own roughly 16% of the combined company and former Treeline holders about 84%, with final percentages adjusted to Standard BioTools’ net cash at closing.
Standard BioTools must seek stockholder approval for issuing new shares, amending its charter and adopting new equity plans, and must pursue monetization or wind-down of its mass cytometry and microfluidics businesses. Legacy stockholders are expected to receive one contingent value right per share, with potential payments in stock over five years tied to net proceeds from divesting legacy assets and certain existing investments, up to a maximum of 76,000,000 shares. The combined company is expected to have more than $900 million in cash at closing, with runway projected into 2029, and will be led by Treeline’s management team.
Standard BioTools Inc. has regained compliance with Nasdaq’s minimum bid price rule. On June 5, 2026, the company received notice from Nasdaq’s Listing Qualifications Staff confirming that it now meets Nasdaq Listing Rule 5450(a)(1), which requires a bid price of at least $1.00 per share. The issue arose after an April 20, 2026 notice that the company’s common stock had closed below $1.00 for 30 consecutive business days. Nasdaq has now closed this matter, and the company’s common stock continues to trade on the Nasdaq Global Select Market under the symbol LAB.
Standard BioTools Inc. approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay under its 2026 Equity Incentive Plan, effective June 20, 2026. If he continues providing services, 40% of the award will vest on June 20, 2027 and the remaining 60% on June 20, 2028. The award is governed by the 2026 Equity Incentive Plan, its RSU agreement, and the company’s 2026 Change of Control and Severance Plan and related participation agreement.
Standard BioTools Inc. approved new and updated executive severance plans that define cash, equity and benefit protections upon certain terminations and change of control events. The 2026 Change of Control and Severance Plan, effective through August 4, 2028, covers the executive leadership team other than the CEO, with Alex Kim (CFO) and Sean MacKay (Chief Business Officer) entering participation agreements.
Outside a change of control period, covered executives may receive 100% of annual base salary over 12 months, a pro-rated target bonus, up to 12 months of health coverage reimbursement, potential accelerated equity vesting for terminations on or before August 27, 2026, and outplacement services. If terminated within a defined change of control period, they may receive a lump sum equal to 150% of salary plus specified bonus metrics, a pro-rated target bonus, up to 18 months of health coverage reimbursement, and full equity acceleration.
The Board also approved an amended and restated 2023 Change of Control and Severance Plan for CEO Michael Egholm, Ph.D., as sole participant, with an initial term through August 4, 2028. Outside a change of control period, the CEO is eligible for 200% of base salary over 24 months, up to 12 months of health coverage reimbursement and outplacement services. If terminated within a change of control period, the CEO may receive a lump sum equal to 250% of salary plus specified bonus metrics, a pro-rated target bonus, up to 30 months of health coverage reimbursement, and full acceleration of unvested equity awards.